P2.06. Phase I/II Study of Rucaparib and Pembrolizumab Maintenance in Stage IV NSCLC after Carboplatin, Pemetrexed, Pembrolizumab - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Angel Qin
Meta Tag
Speaker Angel Qin
Topic Metastatic NSCLC: Immunotherapy - Prospective
Keywords
maintenance therapy
PARP inhibitor
rucaparib
checkpoint inhibitor
pembrolizumab
stage IV non-small cell lung cancer
NSCLC
standard of care treatment
progression-free survival
phase I/II trial
Powered By